Nilda Mesa Sells 255 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHRGet Free Report) Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Nilda Mesa also recently made the following trade(s):

  • On Friday, November 8th, Nilda Mesa sold 224 shares of United Therapeutics stock. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72.

United Therapeutics Stock Performance

United Therapeutics stock traded down $4.80 during midday trading on Tuesday, hitting $352.84. 266,757 shares of the company’s stock were exchanged, compared to its average volume of 443,397. The stock has a market cap of $15.75 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 1.05 and a beta of 0.55. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm’s 50 day simple moving average is $370.41 and its 200 day simple moving average is $349.43.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the business earned $5.38 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after acquiring an additional 45,566 shares in the last quarter. FMR LLC grew its stake in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. LSV Asset Management raised its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group increased their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Get Our Latest Research Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.